NEWS
Quotient Sciences Announces Multimillion-Pound Investment in Drug Substance Manufacturing Facility
Read article
Developing an inhaled drug product
Inhaled drug development
Quotient has a 30 year track record in the development and manufacturing of inhaled drug products. We have experience across a range of drug delivery platforms including dry powder inhalers (DPIs) and solutions/suspensions for inhalation.
With integrated capabilities and vast knowledge of nasal and pulmonary delivery, we help our clients accelerate their molecules from first-in-human, through to proof-of-concept and into full development.
Integrated capabilities and expertise for nasal and pulmonary delivery
Our extensive expertise and capabilities for nasal and pulmonary delivery include:
- Pre-formulation and API characterization
- Formulation and process development
- Inhaled device evaluation and selection
- Clinical manufacturing and supply (Phase I-III)
- Clinical pharmacology assessments
We have a wide range of processing and analytical equipment to support the development and manufacture of inhaled drug products:
- Spray drying
- Micronization
- Blending and encapsulation
- Aerosol characterization
Related links
Learn more about inhaled drug development
-
Scientific PostersPhase 1/1b study of inhaled formulation in healthy volunteers & asthmaticsPUR1900 is an iSPERSE™ formulation incorporating a large, complex anti-fungal compound that can be administered at high therapeutic dose to the lung while minimizing systemic side effects.
-
Info SheetInhaled Product DevelopmentWith more than 30 years’ experience, Quotient is a leader in the development, manufacture and assessment of inhalation products, helping clients to accelerate molecules from first-in-human through to proof-of-concept.
-
Scientific PostersApplication of Translational Pharmaceutics® to reduce time, cost and risk in the early development of inhaled drug products - RDDThe efficiency and effectiveness of new drug development has remained problematic over the last decade. Translational Pharmaceutics has emerged as a new paradigm to improve R&D productivity.
-
Scientific PostersEuPFI 2021 - Taste Assessment Study of Belumosudil to Inform an Integrated Paediatric Formulation Development ProgramPresentied at the annual EuPFI event, this poster dicuments the project of Belumosudil, a ROCK2 selective inhibitor, is currently in development for the treatment of immune disorders.
Ready to get started?
Share your project needs with us.
We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.